Ironwood Stockholders Approve 10M Share Increase for Equity Plan

Ironwood Pharmaceuticals held its 2026 Annual Meeting of Stockholders, where key proposals were approved. Stockholders voted to approve an amendment to the company's Amended and Restated 2019 Equity Incentive Plan, increasing the shares available for issuance by 10,000,000. Additionally, eight director nominees were elected, executive compensation was approved on a non-binding advisory basis, and KPMG LLP was ratified as the independent registered public accounting firm for 2026.